The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of chronic hepatitis B: Evolution over two decades
Open accessAbstract
There has been a recent paradigm shift in the indications and endpoints of treatment for chronic hepatitis B (CHB). Hepatitis B e antigen (HBeAg)‐negative disease is being increasingly recognized. Antiviral treatment for both HBeAg‐positive and HBeAg‐negative patients should aim at long‐term suppression of HBV DNA, with the ultimate ideal endpoint of hepatitis B surface antigen (HBsAg) seroconversion. Conventional interferon alpha (IFN‐α), the only agent licensed in 1991, has been superseded by pegylated IFN‐α. HBeAg seroconversion using pegylated IFN‐α is 33%, with only 25% of HBeAg‐positive patients achieving undetectable HBV DNA by polymerase chain reaction (PCR) assay. Five nucleoside/nucleotide analogues have been licensed since 1998. Lamivudine, an L‐nucleoside, is limited by the development of resistance in 76% of patients after 5 years of therapy. Telbivudine, another L‐nucleoside, is more potent than lamivudine but resistance still develops in 25% of HBeAg‐positive and 11% HBeAg‐negative patients after 2 years. Adefovir, an acyclic phosphonate, is relatively weak, but is effective against lamivudine‐ and telbivudine‐ resistant mutations, for which it should be used in combination (add‐on therapy) rather than substituted. Resistance to adefovir develops slowly, rising to 29% for HBeAg‐negative patients by year 5, but more rapidly when used alone for lamivudine‐resistant HBV. Currently the two first line nucleoside/nucleotides are entecavir and tenofovir. Entecavir, a cyclopentane (D‐nucleoside), is very potent, with 94% of patients having undetectable HBV DNA after 5 years. Resistance develops in only 1.2% of treatment‐naïve patients. Tenofovir, another acyclic nucleotide, is more potent with less renal toxicity compared to adefovir. It is effective against lamivudine‐resistant mutations when used alone. No resistance to tenofovir has been described after its use for 3 years or longer, often for patients with human immunodeficiency virus/HBV co‐infection. With these current, potent antiviral agents associated with very low rates of resistance, long‐term HBV DNA suppression and possibly even reversal of cirrhosis can now be achieved in a proportion of patients. In addition, long‐term treatment with these antiviral agents is associated with a reduced risk of development of hepatocellular carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Cited by
Wu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T. (2012) · JAMA · doi:10.1001/2012.jama.11975 · Cited by 818
Wu, C.-Y., Lin, J.-T., Ho, H. J., Su, C.-W., Lee, T.-Y., Wang, S.-Y., Wu, C., & Wu, J.-C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.048 · Cited by 319
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
Metadata
- Authors
- Yuen, M., & Lai, C.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 26
- Issue
- s1
- Pages
- 138-143
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W1513593427
- Cited by
- 164
- References
- 1
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of chronic hepatitis B: Evolution over two decades. https://app.cochat.ai/papers/10.1111/j.1440-1746.2010.06545.x
- The paper
- Yuen, M., & Lai, C. (2011). Treatment of chronic hepatitis B: Evolution over two decades. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2010.06545.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.